Written by Admin | Sep 2, 2020
AlleyWatch caught up with CEO Carolyn Magill to learn more about how the company powers regulators, biopharma, payers, and health technology assessment (HTA) bodies, the company’s future plans, and Aetion’s Series B, which brings the total round size to $82B extension.
Read More